Skip to main content Skip to navigation
Hamburger Menu
Search icon
Order lookup icon Order lookup icon
Order Lookup
Location Selector Location Selector
United States (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Link Arrow
Solutions

Link Arrow
Discover & Learn

Link Arrow
Resources & Tools

Link Arrow
Support

Link Arrow
Search icon Search icon
Close Menu
      Website Feedback
      Alert Icon
      BD OMICS-One™ WTA Next Assay

      Overview

      The BD OMICS-One™ WTA Next Assay redefines single-cell RNA-seq with breakthrough sensitivity and unbiased whole transcriptome profiling. Generate highly reproducible data on the BD Rhapsody™ Single-Cell Analysis System—whether running standalone RNA-seq workflows or integrating with CITE-seq, ATAC-seq or immune repertoire workflows. The new BD OMICS-One™ WTA Next Assay produces consistent, high-quality results across all multiomics applications with cell input ranges from 1,000 to 100,000 per lane on an 8-lane cartridge.
       

      Download the BD OMICS-One™ WTA Next Assay Brochure>

       
      BD WTA NEXT Product Image
      performance1

      Features

      The BD OMICS-One™ WTA Next Assay expands what’s possible—providing superior sensitivity, enhanced multiomics capabilities, greater flexibility, reliable scalability and impactful economic value. The assay also delivers best-in-class sensitivity to reveal rare transcripts and cellular complexity across all supported workflows, exceeding 10x Genomics’ Chromium GEM-X Single Cell 3' v4 Gene Expression Assay in key metrics.

       

      3,000+ Genes per Cell

      • Superior sensitivity for rare transcripts analysis
      • Unbiased detection across the entire transcriptome

      Scalable Throughput

      • Process up to 100,000 cells per lane (800,000 cells per cartridge)
      • Reliable performance across a wide range of cell inputs

      Multiomics Excellence

      • Enhanced gene expression analysis with CITE-seq and TCR/BCR assays
      • Significant gene recovery with ATAC-seq

      Lower Cost per Sample

      • Better performance at reduced per-sample cost
      • Less sequencing depth required for equivalent results

      Flexible Sample Handling

      • Fresh processing or 72-hour storage at 4 °C
      • Long-term cryopreservation option
      		 

      Performance

      The BD OMICS-One™ WTA Next Assay delivers superior performance across key sensitivity metrics at different sequencing depths.

      Head-to-head comparison of the BD OMICS-One™ WTA Next Assay versus the 10x Genomics Chromium GEM-X Single Cell 3' v4 Gene Expression Assay using matched PBMC samples from three donors processed under identical conditions.
      WTA NEXT Superior Performance Across Key Sensitivity Markers

      Bar graphs show median UMIs (A) and median genes per cell (B) at 25,000 and 50,000 raw sequencing reads per cell. The BD OMICS-One™ WTA Next Assay achieves higher molecular and gene detection that becomes increasingly more pronounced as sequencing depth increases, demonstrating best-in-class sensitivity for single-cell RNA sequencing applications. Error bars represent standard deviation across three biological replicates.

      The BD OMICS-One™ WTA Next Assay captures a significantly higher number of molecules and genes per cell at the same sequencing depth

      Performance comparison of the new BD OMICS-One™ WTA Next Assay (WTA Next) versus the current BD Rhapsody™ Whole Transcriptome Analysis (WTA) Assay using previously frozen PBMC samples from three healthy matched donors processed in standalone WTA experiments.
      WTA NEXT Higher Molecule and Gene Capture

      (A) Median number of unique molecular identifiers (UMIs) per cell as a function of raw sequencing reads per cell, demonstrating a 120% increase in transcript detection with WTA Next at 50,000 reads per cell. 

      (B)       Median number of genes detected per cell across varying sequencing depths, showing a 67% improvement with WTA Next at 50,000 reads per cell. Error bars represent standard deviation across three biological replicates. .WTA workflow: 20,000 cells targeted with ~16,000 recovered, subsampled to 4,000 for analysis. WTA Next workflow: 40,000 cells targeted with ~30,000 recovered, subsampled to 3,000 cells. All captures were performed on a BD Rhapsody™ 8-Lane Cartridge.

      The BD OMICS-One™ WTA Next Assay enhances gene expression analysis across all supported multiomic workflows.

      Gene recovery comparison between the current BD Rhapsody™ Whole Transcriptome Analysis (WTA) Assay and new BD OMICS-One™ WTA Next Assay (WTA Next) across different multiomics applications.
      WTA Next Assay Enhanced Gene Expression

      (A) Cell-based workflows using frozen PBMCs. Left: CITE-seq showing 38% increase in median genes per cell with WTA Next at ~23,000 reads per cell. Right: TCR/BCR-based assay demonstrating 81% improvement with WTA Next at ~22,700 reads per cell.

      (B) Nuclei-based workflows using fresh PBMCs. Left: ATAC-seq showing 156% increase in median genes per cell with WTA Next at 25,000 reads per cell. Right: Multiplexed ATAC-seq demonstrating 126% improvement with WTA Next at 25,000 reads per cell. The BD OMICS-One™ WTA Next Assay delivers substantial performance gains across all supported multiomic combinations, either in single-cell or nuclei-based implementations.

      The BD OMICS-One™ WTA Next Assay delivers consistent results across different users and experiments.

      Reproducibility assessment with two independent users processing the same frozen PBMC sample from one donor in separate experiments (with 30,000 cells).
      WTA Next Consistent Results

      (A) Bar graphs show nearly identical median UMIs (left) and median genes (right) per cell at 25,000 reads per cell, confirming consistent sensitivity across users.

      (B) Gene expression correlation (R2 = 1.0) demonstrating exceptional inter-user reproducibility, confirming robust assay performance independent of operator variability. Consistent results across users ensure reliable data generation in multi-operator laboratories and collaborative research settings.

      Applications

      The BD OMICS-One™ WTA Next Assay’s enhanced sensitivity and unbiased profiling enable breakthrough discoveries across immunology, oncology, neuroscience, developmental biology and drug discovery.

      WTA Next Distinct Cell Population Identification and Resolution
      performance1

      Identification and resolution of distinct immune cell populations in PBMC samples

      Distinct Cell Population Identification and Resolution Expanded
      performance1

      Gene expression distributions across immune cell types

      WTA Next Assay Deeper Immune Profiling Ability
      performance1

      Immune profiling ability to resolve functional subpopulations within major cell types

      Frequently Asked Questions


      Download our FAQ document if you have more in-depth questions>
       

      1. How does the performance of the new BD OMICS-One™ WTA Next Assay compare to the current BD Rhapsody™ Whole Transcriptome Analysis (WTA) Assay? The BD OMICS-One™ WTA Next Assay delivers significant improvements in molecule and gene recovery. We observed an average 120% and 67% increase in molecule and gene detection, respectively, across three PBMC donors at 50,000 reads per cell.

      2. How does the performance of multiomic assays compare to assays run on the BD Rhapsody™ WTA Assay? The BD OMICS-One™ WTA Next Assay enhances gene recovery across all multiomics workflows. Improvements are workflow-dependent, ranging from ~40% increase with CITE-seq to ~155% with ATAC-seq at 25,000 reads per cell.

      3. How does the BD OMICS-One™ WTA Next Assay compare to the 10x Genomics GEM-X v4 Assay? BD OMICS-One™ WTA Next Assay exceeds GEM-X assay across key metrics. In head-to-head comparisons, we recovered ~5% more genes per cell at 50,000 reads per cell, delivering unmatched performance in single-cell RNA-seq analysis.

      4. What are the key differences between the BD OMICS-One™ WTA Next Assay and BD Rhapsody™ WTA Assay workflows? The BD OMICS-One™ WTA Next Assay features optimized reagents and refined processing steps that enhance sensitivity without changing the fundamental workflow. Contact our Support team for detailed protocol comparisons specific to your application.

      5. Can I use my existing protocols? No. The BD OMICS-One™ WTA Next Assay, for the most part, maintains the same workflow as the BD Rhapsody™ WTA Assay with identical hands-on time and processing steps but you must use the updated protocols.

      6. Is the BD OMICS-One™ WTA Next Assay compatible with BD® Single-Cell Multiplexing Kits, BD® AbSeq Antibody-Oligos and BD Rhapsody™ ATAC-Seq and TCR/BCR Next Assays? Absolutely. The BD OMICS-One™ WTA Next Assay maintains full compatibility while delivering enhanced gene expression performance across all supported multiomics workflows.

      7. Is the BD OMICS-One™ WTA Next Assay more cost-effective than the BD Rhapsody™ WTA Assay? Yes, the BD OMICS-One™ WTA Next Assay reduces per-sample costs by up to 10% compared to the BD Rhapsody™ WTA Assay despite enhanced performance.

      8. Can I store samples before processing? Yes. In addition to fresh processing, you can store your samples at 4 °C for up to 72 hours in BD® OMICS-Guard Sample Preservation Buffer or cryopreserve them for long-term storage with our cryopreservation solution.

      9. How many cells can I process? You can load up to 100,000 cells per lane on our 8-lane cartridge and capture 80%+ of 800,000 cells per full cartridge run.

      10. Will the BD Rhapsody™ WTA Assay remain available once the BD OMICS-One™ WTA Next Assay is launched? The main amplification kit for the BD Rhapsody™ WTA Assay (Cat. No. 633801) will phase out as the BD OMICS-One™ WTA Next Assay kit becomes available. We recommend transitioning to the BD OMICS-One™ WTA Next Assay for superior performance and economics.

         

        

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.